Your Health, We Care
Mirdametinib is a prescription medicine indicated for adult patients and children aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be completely removed by surgery.
The safety and efficacy of mirdametinib in children under 2 years of age have not been established.
Mirdametinib is a MEK inhibitor classified as targeted therapy, rather than conventional chemotherapy. Its mechanism of action involves blocking specific signaling pathways in the body that drive the growth of plexiform neurofibromas.
FDA，2025.11
A therapy for the treatment of adult and pediatric patients aged 2 years and old···【more】
Release date：2026-10-21Recommended：5
Most common side effects of mirdametinib in adultsAccording to clinical trial da···【more】
Release date：2026-06-09Recommended：266
What is Mirdametinib?Mirdametinib is a prescription medicine specifically used t···【more】
Release date：2026-06-09Recommended：286
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
